DEBRA LAING GRAYMAN, MD

7932 West Sand Lake Road, Suite 206

Orlando, Florida 32819

407-900-2580

[email protected]

 

Education

Bachelor of Science in Microbiology, University of Florida

Gainesville, Florida

1993-1997

Doctor of Medicine, Morehouse School of Medicine

Atlanta, Georgia

1997-2001

Internship

Department of General Surgery, University Hospitals of Cleveland

Cleveland, Ohio

2001-2002

Residency

Resident-Dermatology Department, St. Luke’s-Roosevelt Hospital Center

New York, New York

2003-2006

     

 

Certifications – Board and Other

Diplomate, American Board of Dermatology

 

 

Licensure

Florida

ME 98190

 

Employment

Teaching Assistant, Morehouse School of Medicine – Department of Psychiatry

Atlanta, Georgia

1999-2000

Teaching Assistant, Morehouse School of Medicine – Department of Pathology

Atlanta, Georgia

1999-2000

Dermatologist, Debra Price, MD, PA

Miami, Florida

2007-2008

Dermatologist, Onsite Dermatology

Boca Raton, Florida

2008-2009

Dermatologist, Associates in Dermatology

Orlando, Florida

2009-2011

Dermatologist, Locum Tenens Staffing Companies

Orlando, Florida

2011-2012

Dermatologist / Medical Director, Pure Skin Dermatology & Aesthetics

7932 West Sand Lake Road, Suite 206, Orlando, Florida 32819

2012-Present

 

Clinical Research / Medical Training

CITI GCP On-line Course

2019

 

Society Membership / Committees

American Academy of Dermatology

2003-Present

Mentor Facial Filler Advisory Board

2003

Women’s Dermatological Association

2003-2006

Physicians United Plan, Medical Advisory Committee

2012-2015

Alpha Kappa Alpha Sorority, Inc. – Psi Theta Omega Chapter

2013-Present

 

 

 

 

Speaker Experience

Speaker, Amirall Speaker Program (Seysara)

2019-2020

Speaker, Journey Medical Speaker Program (Ximino, Targadox, Accutane, Exelderm)

2021-Present

Speaker, Galderma Speaker Program (Epsolay)

2022-Present

Speaker, Galderma Acne & Rosacea Speaker Program

March 2023-Present

Arcutis Virtual Advisory Board

April 2023

Speaker, Alma Academy Spring Forum

May 2023

Incyte Dermatology Virtual Advisory Board

May 2023

 

 

Affiliations

Investigator, Accel Research Sites – Pure Skin Dermatology & Aesthetics

7932 West Sand Lake Road, Suite 206, Orlando, Florida 32819

2019-Present

Investigator, Accel Research Sites – DeLand Clinical Research Unit

860 Peachwood Drive, DeLand, Florida 32720

2019-Present

Accel Research Sites

615 Crescent Executive Court, Suite 120, Lake Mary, Florida, 32746

2020-Present

 

Publications & Presentations

Grayman DL, Alexis AR, Taylor SC. Central Centrifugal Cicatricial Alopecia: An Update. Manuscript in Progress.

Groner A, Grayman D, Silverberg N. Outpatient Pediatric Community Associated MRSA: A Polymorphous Clinical Disease. Accepted for Publication in Cutis January 2008.

Acne in Skin of Color: Issues and Approaches to Treatment. May 11, 2006. accessdermatology.com

Presentation: An Unusual Presentation of Systemic Lupus Erythematosus in Pregnancy. Presented at American Academy of Dermatology Meeting. February 2004

Perez M, Grayman DL. Nonablative Laser Resurfacing. Cosmetic Dermatology. March 2005

Presentation: A Survey of the Knowledge, Attitudes, and Beliefs of Individuals Concerning Vaccinating their Children. Presented at a Research Symposium, Morehouse School of Medicine. October 1998

Presentation: A Survey of the Knowledge, Attitudes, and Beliefs of Individuals Concerning Vaccinating their Children. Presented at the NCID Research Symposium. July1998

Presentation: The Maroons: A Fight for Freedom. Ronald McNair Research Day. April 1997

 

Principal Investigator Clinical Research Experience

Dermatology (Count: 7)

Arcutis ARQ-151-302: A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis.

2020

DermaSensor: DERMaSensor Use as an Adjunctive Tool in the ASSESSment of Skin Lesions Suggestive of Melanoma III (DERM-ASSESS III).

2020

Pfizer B7451050: A Phase 3B Randomized, Double-Blind, Double-Dummy, Active
Controlled Multi-Center Study Assessing the Efficacy and Safety of Abrocitinib Compared with Dupilumab In Adult Participants on Background Topical Therapy with Moderate to Severe Atopic Dermatitis.

2020

UCB HS0004: A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects with Moderate to Severe Hidradenitis Suppurativa.

2020

AbbVie – M15-999: This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel group study that will evaluate the safety and efficacy of the STUDY DRUG in patients with moderate to severe plaque psoriasis.

2019

ChemoCentryx – CL016_168 (Aurora): A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects with Moderate to Severe Hidradenitis Suppurativa.

2019

Xbiotech, Inc. – 2019-PT047: A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients with Moderate to Severe Hidradenitis Suppurativa.

2019

Sub-Investigator Clinical Research Experience

Dermatology (Count: 3)

Pfizer B7451015: A Phase 3 Multi-center, long-term extension study investigating the efficacy and safety of PF-04965842, with or without topical medications, administered to subjects aged 12 years and older with moderate to severe atopic dermatitis.

2019

Pfizer B7451036: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Investigating the Efficacy and Safety of PF-04965842 Co-administered with Background Medicated Topical Therapy in Adolescent Participants 12 TO <18 Years of Age with Moderate to Severe Atopic Dermatitis.

2019

Pfizer B7931023: A Phase 2B, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild to Moderate Chronic Plaque Psoriasis.

2019